Any feedback?
Information on EC 3.1.3.46 - fructose-2,6-bisphosphate 2-phosphatase
for references in articles please use BRENDA:EC3.1.3.46Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.1.3.46 fructose-2,6-bisphosphate 2-phosphataseIUBMB Comments
The enzyme copurifies with EC 2.7.1.105 6-phosphofructo-2-kinase. (cf. EC 3.1.3.54 fructose-2,6-bisphosphate 6-phosphatase).
Specify your search results
Word Map
- 3.1.3.46
- fructose-1,6-bisphosphatase
-
gluconeogenesis
-
gluconeogenic
- amp
- 6-phosphate
-
1,6-bisphosphatase
-
tp53-induced
- phosphoenolpyruvate
- isozyme
- chloroplast
- endothelial
- glycogen
- pentose
- 6-phosphofructo-1-kinase
- hepatocytes
-
carboxykinase
- fructose-6-phosphate
-
hypoxia-inducible
- glucokinase
-
camp-dependent
-
warburg
- pepck
-
3.1.3.11
-
glucose-induced
- g6pase
- spinach
- hk2
-
fructose-1
- hypoglycemia
- glucose-6-phosphatase
- hexokinase
-
fru-6-p
-
glycogenolysis
-
calvin
-
p53-inducible
-
anaphase-promoting
- phosphofructokinase-1
- phosphoenzyme
-
fructose-6-p
- molecular biology
- medicine
- pharmacology
- agriculture
-
pentose-phosphate
-
z-line
The expected taxonomic range for this enzyme is: Bacteria, Eukaryota
Synonyms
fbpase, pfkfb3, tigar, pfk-2, pfkfb4, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, fructose-2,6-bisphosphatase, pfkfb2, pfk-2/fbpase-2, f-2,6-p2, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
D-fructose-2,6-bisphosphatase
-
-
-
-
fructose-2,6-bisphosphatase
-
-
-
-
fructose-2,6-diphosphatase
-
-
-
-
phosphatase, fructose 2,6-di-
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
beta-D-fructose 2,6-bisphosphate + H2O = D-fructose 6-phosphate + phosphate
FBPase performs a reaction following a classical ping pong mechanism with formation of a phosphoryl-enzyme intermediate on a histidine residue located in an Arg-His-Gly triad, catalytic site structure, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hydrolysis of phosphoric ester
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
beta-D-fructose-2,6-bisphosphate 2-phosphohydrolase
The enzyme copurifies with EC 2.7.1.105 6-phosphofructo-2-kinase. (cf. EC 3.1.3.54 fructose-2,6-bisphosphate 6-phosphatase).
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
81611-75-8
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
beta-D-fructose 2,6-bisphosphate + H2O
D-fructose 6-phosphate + phosphate
-
-
-
?
beta-D-fructose 2,6-bisphosphate + H2O
D-fructose 6-phosphate + phosphate
metabolic regulation of isozyme PFKFB3
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
beta-D-fructose 2,6-bisphosphate + H2O
D-fructose 6-phosphate + phosphate
metabolic regulation of isozyme PFKFB3
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Habitual
Acceleration of the glycolytic flux by steroid receptor coactivator-2 is essential for endometrial decidualization.
Acidosis
Characterization of human fructose-1,6-bisphosphatase in control and deficient tissues.
Acidosis
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.
Acidosis
Fructose-1,6-bisphosphatase deficiency as a cause of recurrent hypoglycemia and metabolic acidosis: Clinical and molecular findings in Malaysian patients.
Acidosis
Intravenous glycerol therapy should not be used in patients with unrecognized fructose-1,6-bisphosphatase deficiency.
Acidosis, Lactic
Fructose-1,6-bisphosphatase deficiency with confirmed molecular diagnosis. An important cause of hypoglycemia in children.
Acidosis, Lactic
Novel compound heterozygous mutations in the fructose-1,6-bisphosphatase gene cause hypoglycemia and lactic acidosis.
Acidosis, Lactic
Pitfall in the Diagnosis of Fructose-1,6-Bisphosphatase Deficiency: Difficulty in Detecting Glycerol-3-Phosphate with Solvent Extraction in Urinary GC/MS Analysis.
Acute Kidney Injury
LncRNA XIST serves as a ceRNA to regulate the expression of ASF1A, BRWD1M, and PFKFB2 in kidney transplant acute kidney injury via sponging hsa-miR-212-3p and hsa-miR-122-5p.
Acute Lung Injury
Ablation of endothelial Pfkfb3 protects mice from acute lung injury in LPS-induced endotoxemia.
Acute Lung Injury
Blockage of glycolysis by targeting PFKFB3 alleviates sepsis-related acute lung injury via suppressing inflammation and apoptosis of alveolar epithelial cells.
Adenocarcinoma
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer.
Adenocarcinoma
Dynamic ROS Regulation by TIGAR: Balancing Anti-cancer and Pro-metastasis Effects.
Adenocarcinoma
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Adenocarcinoma
Expression of TIGAR and its correlation with clinicopathology, prognosis, and 18F-FDG PET/CT parameters in patients with resectable pancreatic ductal adenocarcinoma.
Adenocarcinoma
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
Adenocarcinoma
Studying Antitumor Effects of Sirna Gene Silencing of some Metabolic Genes in Pancreatic Ductal Adenocarcinoma.
Adenocarcinoma
The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma.
Adenocarcinoma of Lung
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Adenocarcinoma of Lung
High expression of synthesis of cytochrome c oxidase 2 and TP53-induced glycolysis and apoptosis regulator can predict poor prognosis in human lung adenocarcinoma.
Adenocarcinoma of Lung
PFKFB4 promotes lung adenocarcinoma progression via phosphorylating and activating transcriptional coactivator SRC-2.
Adenocarcinoma of Lung
Plasminogen/plasmin affects expression of glycolysis regulator TIGAR and induces autophagy in lung adenocarcinoma A549 cells.
Adenocarcinoma of Lung
Structure-based design of small-molecule ligands of phosphofructokinase-2 activating or inhibiting glycolysis.
Adenoma
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer.
Adenoma
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
Alzheimer Disease
NF-?B-Induced Upregulation of miR-146a-5p Promoted Hippocampal Neuronal Oxidative Stress and Pyroptosis via TIGAR in a Model of Alzheimer's Disease.
Astrocytoma
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas.
Astrocytoma
Prognostic Value of PFKFB3 to PFKFB4 mRNA Ratio in Patients With Primary Glioblastoma (IDH-Wildtype).
Astrocytoma
The PFKFB3 splice variant UBI2K4 is down-regulated in high-grade astrocytomas and impedes the growth of U87 glioblastoma cells.
Atherosclerosis
Inhibition of PFKFB3 Hampers the Progression of Atherosclerosis and Promotes Plaque Stability.
Atherosclerosis
Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis.
Atherosclerosis
TIGAR mitigates atherosclerosis by promoting cholesterol efflux from macrophages.
Atherosclerosis
[18F]ZCDD083: A PFKFB3-Targeted PET Tracer for Atherosclerotic Plaque Imaging.
Autoimmune Diseases
First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes.
Bacterial Infections
Signatures of selection reveal candidate genes involved in economic traits and cold acclimation in five Swedish cattle breeds.
Brain Edema
Intravenous glycerol therapy should not be used in patients with unrecognized fructose-1,6-bisphosphatase deficiency.
Brain Injuries
A TIGAR-regulated metabolic pathway is critical for protection of brain ischemia.
Brain Injuries
The E3 ubiquitin ligase TRIM31 is involved in cerebral ischemic injury by promoting degradation of TIGAR.
Brain Injuries
TIGAR alleviates ischemia/reperfusion-induced autophagy and ischemic brain injury.
Brain Injuries
TIGAR contributes to ischemic tolerance induced by cerebral preconditioning through scavenging of reactive oxygen species and inhibition of apoptosis.
Brain Ischemia
A TIGAR-regulated metabolic pathway is critical for protection of brain ischemia.
Brain Ischemia
PFKFB3-mediated glycolysis is involved in reactive astrocyte proliferation after oxygen-glucose deprivation/reperfusion and is regulated by Cdh1.
Brain Ischemia
The E3 ubiquitin ligase TRIM31 is involved in cerebral ischemic injury by promoting degradation of TIGAR.
Breast Neoplasms
6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
Breast Neoplasms
Aberrant methylation of human L- and M-fructose 1,6-bisphosphatase genes in cancer.
Breast Neoplasms
AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest.
Breast Neoplasms
CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism.
Breast Neoplasms
Downregulation of caveolin?1 upregulates the expression of growth factors and regulators in co?culture of fibroblasts with cancer cells.
Breast Neoplasms
Downregulation of TIGAR sensitizes the antitumor effect of physapubenolide through increasing intracellular ROS levels to trigger apoptosis and autophagosome formation in human breast carcinoma cells.
Breast Neoplasms
Estradiol Stimulates Glucose Metabolism via 6-Phosphofructo-2-kinase (PFKFB3).
Breast Neoplasms
High expression of metabolic enzyme PFKFB4 is associated with poor prognosis of operable breast cancer.
Breast Neoplasms
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.
Breast Neoplasms
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Breast Neoplasms
Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer.
Breast Neoplasms
Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4.
Breast Neoplasms
Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting.
Breast Neoplasms
PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer.
Breast Neoplasms
PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis.
Breast Neoplasms
PFKFB3 potentially contributes to paclitaxel resistance in breast cancer cells through TLR4 activation by stimulating lactate production.
Breast Neoplasms
PFKFB4 Promotes Breast Cancer Metastasis via Induction of Hyaluronan Production in a p38-Dependent Manner.
Breast Neoplasms
Positive regulation of PFKFB3 by PIM2 promotes glycolysis and paclitaxel resistance in breast cancer.
Breast Neoplasms
Progestins activate 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in breast cancer cells.
Breast Neoplasms
Regulatory role of p53 in cancer metabolism via SCO2 and TIGAR in human breast cancer.
Breast Neoplasms
Sonic hedgehog stimulates glycolysis and proliferation of breast cancer cells: Modulation of PFKFB3 activation.
Breast Neoplasms
Structure-based design of small-molecule ligands of phosphofructokinase-2 activating or inhibiting glycolysis.
Breast Neoplasms
TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer.
Carcinogenesis
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas.
Carcinogenesis
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Carcinogenesis
Identification of the TP53-induced glycolysis and apoptosis regulator in various stages of colorectal cancer patients.
Carcinogenesis
miR-885-5p plays an accomplice role in liver cancer by instigating TIGAR expression via targeting its promoter.
Carcinogenesis
Oncogenic role of the TP53-induced glycolysis and apoptosis regulator in nasopharyngeal carcinoma through NF-?B pathway modulation.
Carcinogenesis
PFKFB4 negatively regulated the expression of histone acetyltransferase GCN5 to mediate the tumorigenesis of thyroid cancer.
Carcinogenesis
PFKFB4 Overexpression Facilitates Proliferation by Promoting the G1/S Transition and Is Associated with a Poor Prognosis in Triple-Negative Breast Cancer.
Carcinogenesis
Prognostic Values of TIGAR Expression and 18F-FDG PET/CT in Clear Cell Renal Cell Carcinoma.
Carcinogenesis
Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets.
Carcinogenesis
TIGAR Promotes Tumorigenesis and Protects Tumor Cells From Oxidative and Metabolic Stresses in Gastric Cancer.
Carcinoma
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family overexpression in human lung tumor.
Carcinoma
Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Carcinoma
Hypoxia-induced hsa-miR-101 promotes glycolysis by targeting TIGAR mRNA in clear cell renal cell carcinoma.
Carcinoma
Increased expression of PFKFB3 in oral squamous cell carcinoma and its association with lymphangiogenesis.
Carcinoma
Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma.
Carcinoma
microRNA-144 inhibits cell proliferation and invasion by directly targeting TIGAR in esophageal carcinoma.
Carcinoma
Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer.
Carcinoma
Prognostic Values of TIGAR Expression and 18F-FDG PET/CT in Clear Cell Renal Cell Carcinoma.
Carcinoma
The role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in esophageal squamous cell carcinoma.
Carcinoma
The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma.
Carcinoma
TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer.
Carcinoma, Hepatocellular
Adenovirus-mediated overexpression of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in gluconeogenic rat hepatoma cells. Paradoxical effect on Fru-2,6-P2 levels.
Carcinoma, Hepatocellular
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Characterization of the human liver fructose-1,6-bisphosphatase gene promoter.
Carcinoma, Hepatocellular
Cloning and expression in Escherichia coli of a rat hepatoma cell cDNA coding for 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.
Carcinoma, Hepatocellular
Coordinated Expression of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase 4 and Heme Oxygenase 2: Evidence for a Regulatory Link between Glycolysis and Heme Catabolism.
Carcinoma, Hepatocellular
Expression and hypoxia-responsiveness of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 in mammary gland malignant cell lines.
Carcinoma, Hepatocellular
Expression of the liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase mRNA in FAO-1 cells.
Carcinoma, Hepatocellular
Fructose 2,6-bisphosphate and the control of glycolysis by growth factors, tumor promoters and oncogenes.
Carcinoma, Hepatocellular
Hormonal control of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene expression in rat hepatoma cells.
Carcinoma, Hepatocellular
Inhibition of glycolytic activator PFKFB3 suppresses tumor growth and induces tumor vessel normalization in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Insulin inhibits glucocorticoid-induced stimulation of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene transcription.
Carcinoma, Hepatocellular
Knockdown of TIGAR by RNA interference induces apoptosis and autophagy in HepG2 hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Long noncoding RNA FIRRE contributes to the proliferation and glycolysis of hepatocellular carcinoma cells by enhancing PFKFB4 expression.
Carcinoma, Hepatocellular
MACC1 expression correlates with PFKFB2 and survival in hepatocellular carcinoma.
Carcinoma, Hepatocellular
PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT.
Carcinoma, Hepatocellular
PFKFB3/HIF-1? feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Phosphorylation of PPAR? at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4.
Carcinoma, Hepatocellular
Rat hepatoma (HTC) cell 6-phosphofructo-2-kinase differs from that in liver and can be separated from fructose-2,6-bisphosphatase.
Carcinoma, Hepatocellular
Two p53-related metabolic regulators, TIGAR and SCO2, contribute to oroxylin A-mediated glucose metabolism in human hepatoma HepG2 cells.
Carcinoma, Intraductal, Noninfiltrating
Relocation of phosphofructokinases within epithelial cells is a novel event preceding breast cancer recurrence that accurately predicts patient outcomes.
Carcinoma, Non-Small-Cell Lung
Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival.
Carcinoma, Non-Small-Cell Lung
Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
The Effect of TIGAR Knockdown on Apoptotic and Epithelial-Mesenchymal Markers Expression in Doxorubicin-Resistant Non-Small Cell Lung Cancer A549 Cell Lines.
Carcinoma, Non-Small-Cell Lung
TIGAR is correlated with maximal standardized uptake value on FDG-PET and survival in non-small cell lung cancer.
Carcinoma, Renal Cell
Hypoxia-induced hsa-miR-101 promotes glycolysis by targeting TIGAR mRNA in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Prognostic Values of TIGAR Expression and 18F-FDG PET/CT in Clear Cell Renal Cell Carcinoma.
Carcinoma, Small Cell
The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma.
Carcinoma, Squamous Cell
Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Cardiovascular Diseases
TIGAR mitigates atherosclerosis by promoting cholesterol efflux from macrophages.
Choroidal Neovascularization
YAP promotes ocular neovascularization by modifying PFKFB3-driven endothelial glycolysis.
Clonorchiasis
Biochemical characterization and functional analysis of fructose-1,6-bisphosphatase from Clonorchis sinensis.
Colitis, Ulcerative
TIGAR is required for efficient intestinal regeneration and tumorigenesis.
Colonic Neoplasms
Insulin induces PFKFB3 gene expression in HT29 human colon adenocarcinoma cells.
Colonic Neoplasms
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Colonic Neoplasms
PFKFB3 Inhibition Attenuates Oxaliplatin-Induced Autophagy and Enhances Its Cytotoxicity in Colon Cancer Cells.
Colonic Neoplasms
Structure-based design of small-molecule ligands of phosphofructokinase-2 activating or inhibiting glycolysis.
Colonic Neoplasms
Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.
Colorectal Neoplasms
Effects of the Novel PFKFB3 Inhibitor KAN0438757 on Colorectal Cancer Cells and Its Systemic Toxicity Evaluation In Vivo.
Colorectal Neoplasms
Identification of the TP53-induced glycolysis and apoptosis regulator in various stages of colorectal cancer patients.
Colorectal Neoplasms
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
Colorectal Neoplasms
Mir-488 alleviates chemoresistance and glycolysis of colorectal cancer by targeting PFKFB3.
Colorectal Neoplasms
Necroptosis pathway blockage attenuates PFKFB3 inhibitor-induced cell viability loss and genome instability in colorectal cancer cells.
Colorectal Neoplasms
PFKFB3 Inhibition Attenuates Oxaliplatin-Induced Autophagy and Enhances Its Cytotoxicity in Colon Cancer Cells.
Colorectal Neoplasms
Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.
Colorectal Neoplasms
TIGAR knockdown enhanced the anticancer effect of aescin via regulating autophagy and apoptosis in colorectal cancer cells.
COVID-19
Meta-analysis of transcriptome datasets: An alternative method to study IL-6 regulation in coronavirus disease 2019.
Dehydration
Inhibition of photosynthesis and energy dissipation induced by water and high light stresses in rice.
Dehydration
Phosphoproteomic Analysis of X enopus laevis Reveals Expression and Phosphorylation of Hypoxia-Inducible PFKFB3 during Dehydration.
Diabetes Mellitus
Cardiac Insulin Signaling Regulates Glycolysis Through Phosphofructokinase 2 Content and Activity.
Diabetes Mellitus
Discovery of N-Arylsulfonyl-Indole-2-Carboxamide Derivatives as Potent, Selective, and Orally Bioavailable Fructose-1,6-Bisphosphatase Inhibitors-Design, Synthesis, In Vivo Glucose Lowering Effects, and X-ray Crystal Complex Analysis.
Diabetes Mellitus
Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes.
Diabetes Mellitus
Low glucose enhanced metformin's inhibitory effect on pancreatic cancer cells by suppressing glycolysis and inducing energy stress via up-regulation of miR-210-5p.
Diabetes Mellitus
[Changes in the level of fructose-2,6-biphosphate in peripheral blood lymphocytes in patients with diabetes mellitus]
Diabetes Mellitus, Type 1
Activation of the HIF1?/PFKFB3 stress response pathway in beta cells in type 1 diabetes.
Diabetes Mellitus, Type 1
Cardiac Insulin Signaling Regulates Glycolysis Through Phosphofructokinase 2 Content and Activity.
Diabetes Mellitus, Type 1
First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes.
Diabetes Mellitus, Type 1
Mononuclear and polymorphonuclear leukocytes show increased fructose-1,6-bisphosphatase activity in patients with type 1 diabetes mellitus.
Diabetes Mellitus, Type 2
A cis-eQTL in PFKFB2 is associated with diabetic nephropathy, adiposity and insulin secretion in American Indians.
Diabetes Mellitus, Type 2
Additive activation of glucokinase by the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and the chemical activator LY2121260.
Diabetes Mellitus, Type 2
Discovery of N-Arylsulfonyl-Indole-2-Carboxamide Derivatives as Potent, Selective, and Orally Bioavailable Fructose-1,6-Bisphosphatase Inhibitors-Design, Synthesis, In Vivo Glucose Lowering Effects, and X-ray Crystal Complex Analysis.
Diabetes Mellitus, Type 2
First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes.
Diabetes Mellitus, Type 2
Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics.
Diabetes Mellitus, Type 2
Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
Diabetes Mellitus, Type 2
Fructose-1,6-bisphosphatase overexpression in pancreatic beta-cells results in reduced insulin secretion: a new mechanism for fat-induced impairment of beta-cell function.
Diabetes Mellitus, Type 2
Increased glucose production in mice overexpressing human fructose-1,6-bisphosphatase in the liver.
Diabetes Mellitus, Type 2
Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in zucker diabetic Fatty rats.
Diabetes Mellitus, Type 2
MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.
Diabetes Mellitus, Type 2
Structure-guided design of AMP mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity.
Diabetic Cardiomyopathies
Sirtuin 3 Alleviates Diabetic Cardiomyopathy by Regulating TIGAR and Cardiomyocyte Metabolism.
Diabetic Nephropathies
A cis-eQTL in PFKFB2 is associated with diabetic nephropathy, adiposity and insulin secretion in American Indians.
Diabetic Neuropathies
TIGAR Attenuates High Glucose-Induced Neuronal Apoptosis via an Autophagy Pathway.
Embolism
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
Endometrial Neoplasms
Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer.
Endometriosis
HSF1 promotes endometriosis development and glycolysis by up-regulating PFKFB3 expression.
Endotoxemia
Ablation of endothelial Pfkfb3 protects mice from acute lung injury in LPS-induced endotoxemia.
Epilepsy
miR-485 inhibits histone deacetylase HDAC5, HIF1? and PFKFB3 expression to alleviate epilepsy in cellular and rodent models.
Epilepsy
TIGAR suppresses seizures induced by kainic acid through inhibiting oxidative stress and neuronal apoptosis.
Esophageal Neoplasms
microRNA-144 inhibits cell proliferation and invasion by directly targeting TIGAR in esophageal carcinoma.
Esophageal Squamous Cell Carcinoma
The role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in esophageal squamous cell carcinoma.
Fanconi Anemia
Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity.
Fanconi Anemia
PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair.
fructose-2,6-bisphosphate 2-phosphatase deficiency
A potential role for muscle in glucose homeostasis: in vivo kinetic studies in glycogen storage disease type 1a and fructose-1,6-bisphosphatase deficiency.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Characterization of human fructose-1,6-bisphosphatase in control and deficient tissues.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Clinical and Molecular Characterization of Patients with Fructose 1,6-Bisphosphatase Deficiency.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Diagnosis of fructose-1,6-bisphosphatase deficiency using cultured lymphocyte fraction: a secure and noninvasive alternative to liver biopsy.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Disruption of endothelial Pfkfb3 ameliorates diet-induced murine insulin resistance.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Fructose 1,6-bisphosphatase deficiency: clinical, biochemical and genetic features in French patients.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Fructose-1,6-bisphosphatase deficiency as a cause of recurrent hypoglycemia and metabolic acidosis: Clinical and molecular findings in Malaysian patients.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Fructose-1,6-bisphosphatase deficiency caused by a novel homozygous Alu element insertion in the FBP1 gene and delayed diagnosis.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Fructose-1,6-bisphosphatase deficiency presented with complex febrile convulsion.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Fructose-1,6-bisphosphatase deficiency with confirmed molecular diagnosis. An important cause of hypoglycemia in children.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Fructose-1,6-Bisphosphatase Deficiency: A Case of a Successful Pregnancy by Closely Monitoring Metabolic Control.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Genetic analysis of fructose-1,6-bisphosphatase (FBPase) deficiency in nine consanguineous Pakistani families.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Genetic analysis of patients with fructose-1,6-bisphosphatase deficiency.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Identification of a response element for vitamin D3 and retinoic acid in the promoter region of the human fructose-1,6-bisphosphatase gene.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Identification of genetic mutations in Japanese patients with fructose-1,6-bisphosphatase deficiency.
fructose-2,6-bisphosphate 2-phosphatase deficiency
International practices in the dietary management of fructose 1-6 biphosphatase deficiency.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Intravenous glycerol therapy should not be used in patients with unrecognized fructose-1,6-bisphosphatase deficiency.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Mice with a specific deficiency of Pfkfb3 in myeloid cells are protected from hypoxia-induced pulmonary hypertension.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Novel compound heterozygous mutations in the fructose-1,6-bisphosphatase gene cause hypoglycemia and lactic acidosis.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Novel Fructose-1,6-bisphosphatase Gene Mutation in Two Siblings.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Novel mutations in patients with fructose-1,6-bisphosphatase deficiency.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Pitfall in the Diagnosis of Fructose-1,6-Bisphosphatase Deficiency: Difficulty in Detecting Glycerol-3-Phosphate with Solvent Extraction in Urinary GC/MS Analysis.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Role of PFKFB3-driven glycolysis in vessel sprouting.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Status epilepticus due to fructose-1,6-bisphosphatase deficiency caused by FBP1 gene mutation.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Three successful pregnancies through dietary management of fructose-1,6-bisphosphatase deficiency.
fructose-2,6-bisphosphate 2-phosphatase deficiency
TIGAR contributes to ischemic tolerance induced by cerebral preconditioning through scavenging of reactive oxygen species and inhibition of apoptosis.
fructose-2,6-bisphosphate 2-phosphatase deficiency
TIGAR is required for efficient intestinal regeneration and tumorigenesis.
fructose-2,6-bisphosphate 2-phosphatase deficiency
TIGAR mitigates atherosclerosis by promoting cholesterol efflux from macrophages.
fructose-2,6-bisphosphate 2-phosphatase deficiency
TIGAR promotes neural stem cell differentiation through acetyl-CoA-mediated histone acetylation.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Two newly identified genomic mutations in a Japanese female patient with fructose-1,6-bisphosphatase (FBPase) deficiency.
Glioblastoma
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas.
Glioblastoma
Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Glioblastoma
Prognostic Value of PFKFB3 to PFKFB4 mRNA Ratio in Patients With Primary Glioblastoma (IDH-Wildtype).
Glioblastoma
RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival.
Glioblastoma
TGF-?1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells.
Glioblastoma
The PFKFB3 splice variant UBI2K4 is down-regulated in high-grade astrocytomas and impedes the growth of U87 glioblastoma cells.
Glioblastoma
TIGAR promotes growth, survival and metastasis through oxidation resistance and AKT activation in glioblastoma.
Glioblastoma
TP53 induced glycolysis and apoptosis regulator (TIGAR) knockdown results in radiosensitization of glioma cells.
Glioblastoma
Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by upregulating respiration and improving cellular redox homeostasis.
Glioma
ATM-NF?B axis-driven TIGAR regulates sensitivity of glioma cells to radiomimetics in the presence of TNF?.
Glioma
IDH1-R132H mutation radiosensitizes U87MG glioma cells via epigenetic downregulation of TIGAR.
Glioma
Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide.
Glioma
Long non-coding RNA UCA1/miR-182/PFKFB2 axis modulates glioblastoma-associated stromal cells-mediated glycolysis and invasion of glioma cells.
Glioma
Radiosensitization of glioma cells by TP53-induced glycolysis and apoptosis regulator knockdown is dependent on thioredoxin-1 nuclear translocation.
Glioma
RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival.
Glioma
TGF-?1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells.
Glioma
TIGAR knockdown radiosensitizes TrxR1-overexpressing glioma in vitro and in vivo via inhibiting Trx1 nuclear transport.
Glioma
TIGAR promotes growth, survival and metastasis through oxidation resistance and AKT activation in glioblastoma.
Glioma
Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by upregulating respiration and improving cellular redox homeostasis.
Glucose Intolerance
[EXPRESSION OF GENES, WHICH CONTROL GLUCOSE METABOLISM, IN BLOOD CELLS OF THE OBESE BOYS WITH INSULIN RESISTANCE].
Heart Diseases
Amylin deposition activates HIF1? and 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3) signaling in failing hearts of non-human primates.
Heart Failure
Ablation of cardiac TIGAR preserves myocardial energetics and cardiac function in the pressure overload heart failure model.
Heart Failure
Amylin deposition activates HIF1? and 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3) signaling in failing hearts of non-human primates.
Hyperglycemia
CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats.
Hyperglycemia
Nuclear accumulation of fructose 1,6-bisphosphatase is impaired in diabetic rat liver.
Hypertension
Involvement of PFKFB3 in Pulmonary Arterial Hypertension Pathogenesis. Is It All about Glycolysis?
Hypertension
PFKFB3 in Smooth Muscle Promotes Vascular Remodeling in Pulmonary Arterial Hypertension.
Hypertension, Pulmonary
Mice with a specific deficiency of Pfkfb3 in myeloid cells are protected from hypoxia-induced pulmonary hypertension.
Hypertension, Pulmonary
TIGAR reduces smooth muscle cell autophagy to prevent pulmonary hypertension.
Hypoglycemia
Characterization of recombinant fructose-1,6-bisphosphatase gene mutations: evidence of inhibition/activation of FBPase protein by gene mutation.
Hypoglycemia
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.
Hypoglycemia
Fructose-1,6-bisphosphatase deficiency as a cause of recurrent hypoglycemia and metabolic acidosis: Clinical and molecular findings in Malaysian patients.
Hypoglycemia
Fructose-1,6-bisphosphatase deficiency presented with complex febrile convulsion.
Hypoglycemia
Fructose-1,6-bisphosphatase deficiency with confirmed molecular diagnosis. An important cause of hypoglycemia in children.
Hypoglycemia
Fructose-1,6-Bisphosphatase Deficiency: A Case of a Successful Pregnancy by Closely Monitoring Metabolic Control.
Hypoglycemia
Intravenous glycerol therapy should not be used in patients with unrecognized fructose-1,6-bisphosphatase deficiency.
Hypoglycemia
JAK2 mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.
Hypoglycemia
Muscle fructose-2,6-bisphosphate and glucose-1,6-bisphosphate during insulin-induced hypoglycemia.
Hypoglycemia
Novel compound heterozygous mutations in the fructose-1,6-bisphosphatase gene cause hypoglycemia and lactic acidosis.
Hypoglycemia
Pitfall in the Diagnosis of Fructose-1,6-Bisphosphatase Deficiency: Difficulty in Detecting Glycerol-3-Phosphate with Solvent Extraction in Urinary GC/MS Analysis.
Hypotension
Alterations in hepatic 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and glucose-6-phosphatase gene expression after hemorrhagic hypotension and resuscitation.
Idiopathic Pulmonary Fibrosis
Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.
Infections
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.
Infections
Genetic Variation in PFKFB3 Impairs Antifungal Immunometabolic Responses and Predisposes to Invasive Pulmonary Aspergillosis.
Infections
Inhibition of eNOS by L-NAME resulting in rat hind limb developmental defects through PFKFB3 mediated angiogenetic pathway.
Infertility
Acceleration of the glycolytic flux by steroid receptor coactivator-2 is essential for endometrial decidualization.
Insulin Resistance
Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease.
Insulin Resistance
Adipocyte inducible 6-phosphofructo-2-kinase suppresses adipose tissue inflammation and promotes macrophage anti-inflammatory activation.
Insulin Resistance
Adipose tissue inflammation and systemic insulin resistance in mice with diet-induced obesity is possibly associated with disruption of PFKFB3 in hematopoietic cells.
Insulin Resistance
Cardiac expression of kinase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase inhibits glycolysis, promotes hypertrophy, impairs myocyte function, and reduces insulin sensitivity.
Insulin Resistance
Disruption of endothelial Pfkfb3 ameliorates diet-induced murine insulin resistance.
Insulin Resistance
Exercise training attenuates oxidative stress and decreases p53 protein content in skeletal muscle of type 2 diabetic Goto-Kakizaki rats.
Insulin Resistance
Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes.
Insulin Resistance
Jejunal gluconeogenesis associated with insulin resistance level and its evolution after Roux-en-Y gastric bypass.
Insulin Resistance
Potential effect of exercise in ameliorating insulin resistance at transcriptome level.
Insulin Resistance
Regulation of hepatic gluconeogenesis and glycogenolysis by phosphorylated glycerol and glycolytic intermediates in diabetic and control Chinese hamsters.
Insulin Resistance
[EXPRESSION OF GENES, WHICH CONTROL GLUCOSE METABOLISM, IN BLOOD CELLS OF THE OBESE BOYS WITH INSULIN RESISTANCE].
Intervertebral Disc Degeneration
TIGAR impedes compression-induced intervertebral disc degeneration by suppressing nucleus pulposus cell apoptosis and autophagy.
Intervertebral Disc Degeneration
TIGAR mediates the inhibitory role of hypoxia on ROS production and apoptosis in rat nucleus pulposus cells.
Intestinal Neoplasms
TIGAR is required for efficient intestinal regeneration and tumorigenesis.
Invasive Pulmonary Aspergillosis
Genetic Variation in PFKFB3 Impairs Antifungal Immunometabolic Responses and Predisposes to Invasive Pulmonary Aspergillosis.
Ischemic Stroke
The E3 ubiquitin ligase TRIM31 is involved in cerebral ischemic injury by promoting degradation of TIGAR.
Ketosis
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.
Ketosis
Pitfall in the Diagnosis of Fructose-1,6-Bisphosphatase Deficiency: Difficulty in Detecting Glycerol-3-Phosphate with Solvent Extraction in Urinary GC/MS Analysis.
Kidney Neoplasms
Glucose metabolism involved in PD-L1-mediated immune escape in the malignant kidney tumour microenvironment.
Leukemia
Reactive Oxygen Species Drive Proliferation in Acute Myeloid Leukemia via the Glycolytic Regulator PFKFB3.
Leukemia
TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.
Leukemia, Monocytic, Acute
PFKFB4 is critical for the survival of acute monocytic leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor.
Leukemia, Myeloid
Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells.
Leukemia, Myeloid, Acute
mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival.
Leukemia, Myeloid, Acute
Reactive Oxygen Species Drive Proliferation in Acute Myeloid Leukemia via the Glycolytic Regulator PFKFB3.
Leukemia, Myeloid, Acute
TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia.
Liver Cirrhosis
CPEB4 Increases Expression of PFKFB3 to Induce Glycolysis and Activate Mouse and Human Hepatic Stellate Cells, Promoting Liver Fibrosis.
Liver Neoplasms
Analysis of Key Genes Regulating the Warburg Effect in Patients with Gastrointestinal Cancers and Selective Inhibition of This Metabolic Pathway in Liver Cancer Cells.
Liver Neoplasms
miR-885-5p plays an accomplice role in liver cancer by instigating TIGAR expression via targeting its promoter.
Liver Neoplasms
PFKFB3, a key glucose metabolic enzyme regulated by pathogen recognition receptor TLR4 in liver cells.
Liver Neoplasms
SP1 plays a pivotal role for basal activity of TIGAR promoter in liver cancer cell lines.
Lung Neoplasms
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family overexpression in human lung tumor.
Lung Neoplasms
Cell cycle-dependent expression and subcellular localization of fructose 1,6-bisphosphatase.
Lung Neoplasms
Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy.
Lung Neoplasms
Fascin promotes lung cancer growth and metastasis by enhancing glycolysis and PFKFB3 expression.
Lung Neoplasms
Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival.
Lung Neoplasms
Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer.
Lung Neoplasms
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Lung Neoplasms
Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer.
Lung Neoplasms
MiR-144 Inhibits Proliferation and Induces Apoptosis and Autophagy in Lung Cancer Cells by Targeting TIGAR.
Lung Neoplasms
Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer.
Lung Neoplasms
Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.
Lung Neoplasms
The Effect of TIGAR Knockdown on Apoptotic and Epithelial-Mesenchymal Markers Expression in Doxorubicin-Resistant Non-Small Cell Lung Cancer A549 Cell Lines.
Lung Neoplasms
TIGAR has a dual role in cancer cell survival through regulating apoptosis and autophagy.
Lung Neoplasms
TIGAR is correlated with maximal standardized uptake value on FDG-PET and survival in non-small cell lung cancer.
Lymphatic Metastasis
Estradiol Stimulates Glucose Metabolism via 6-Phosphofructo-2-kinase (PFKFB3).
Lymphatic Metastasis
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Lymphatic Metastasis
Increased expression of PFKFB3 in oral squamous cell carcinoma and its association with lymphangiogenesis.
Lymphatic Metastasis
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
Lymphatic Metastasis
PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells.
Lymphoma
Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73.
Lymphoma, T-Cell
The TP53-Induced Glycolysis and Apoptosis Regulator mediates cooperation between HTLV-1 p30II and the retroviral oncoproteins Tax and HBZ and is highly expressed in an in vivo xenograft model of HTLV-1-induced lymphoma.
Melanoma
3PO as a Selective Inhibitor of 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 in A375 Human Melanoma Cells.
Melanoma
Analysis of Malignant Melanoma Cell Lines Exposed to Hypoxia Reveals the Importance of PFKFB4 Overexpression for Disease Progression.
Melanoma
Expression of Alternative Splice Variants of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase-4 in Normoxic and Hypoxic Melanoma Cells.
Melanoma
Splice isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4: expression and hypoxic regulation.
Mesothelioma
PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses.
Mesothelioma, Malignant
PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses.
Metabolic Diseases
Fetal expression of genes related to metabolic function is impacted by supplementation of ground beef and sucrose during gestation in a swine model.
Multiple Myeloma
Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH.
Multiple Myeloma
KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells.
Multiple Myeloma
Targeting the MUC1-C oncoprotein is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated multiple myeloma cell death.
Mycoses
Genetic Variation in PFKFB3 Impairs Antifungal Immunometabolic Responses and Predisposes to Invasive Pulmonary Aspergillosis.
Myocardial Infarction
p53 and TIGAR Regulate Cardiac Myocyte Energy Homeostasis Under Hypoxic Stress.
Nasopharyngeal Carcinoma
Oncogenic role of the TP53-induced glycolysis and apoptosis regulator in nasopharyngeal carcinoma through NF-?B pathway modulation.
Nasopharyngeal Carcinoma
PFKFB3 promotes proliferation, migration and angiogenesis in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Prognostic value of TIGAR and LC3B protein expression in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
TP53-induced glycolysis and apoptosis regulator promotes proliferation and invasiveness of nasopharyngeal carcinoma cells.
Neoplasm Metastasis
A Potential Oncogenic Role for PFKFB3 Overexpression in Gastric Cancer Progression.
Neoplasm Metastasis
Angiogenesis revisited from a metabolic perspective: role and therapeutic implications of endothelial cell metabolism.
Neoplasm Metastasis
Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Neoplasm Metastasis
CircFLNA Acts as a Sponge of miR-646 to Facilitate the Proliferation, Metastasis, Glycolysis, and Apoptosis Inhibition of Gastric Cancer by Targeting PFKFB2.
Neoplasm Metastasis
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer.
Neoplasm Metastasis
E2F2 drives glioma progression via PI3K/AKT in a PFKFB4-dependent manner.
Neoplasm Metastasis
Erratum: CircFLNA Acts as a Sponge of miR-646 to Facilitate the Proliferation, Metastasis, Glycolysis, and Apoptosis Inhibition of Gastric Cancer by Targeting PFKFB2 [Corrigendum].
Neoplasm Metastasis
Estradiol Stimulates Glucose Metabolism via 6-Phosphofructo-2-kinase (PFKFB3).
Neoplasm Metastasis
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Neoplasm Metastasis
Fascin promotes lung cancer growth and metastasis by enhancing glycolysis and PFKFB3 expression.
Neoplasm Metastasis
Higher plasma concentration of TP53-induced glycolysis and apoptosis regulator is associated with a lower risk of colorectal cancer metastasis.
Neoplasm Metastasis
Increased expression of PFKFB3 in oral squamous cell carcinoma and its association with lymphangiogenesis.
Neoplasm Metastasis
Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy.
Neoplasm Metastasis
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
Neoplasm Metastasis
Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer.
Neoplasm Metastasis
PFKFB3 promotes proliferation, migration and angiogenesis in nasopharyngeal carcinoma.
Neoplasm Metastasis
PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells.
Neoplasm Metastasis
PFKFB4 Promotes Breast Cancer Metastasis via Induction of Hyaluronan Production in a p38-Dependent Manner.
Neoplasm Metastasis
ROCK2 promotes osteosarcoma growth and metastasis by modifying PFKFB3 ubiquitination and degradation.
Neoplasm Metastasis
Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets.
Neoplasm Metastasis
The role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in esophageal squamous cell carcinoma.
Neoplasm Metastasis
TIGAR promotes growth, survival and metastasis through oxidation resistance and AKT activation in glioblastoma.
Neoplasms
6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia.
Neoplasms
6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27.
Neoplasms
6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer.
Neoplasms
6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells.
Neoplasms
6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
Neoplasms
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas.
Neoplasms
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family overexpression in human lung tumor.
Neoplasms
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 3 spatially mediates autophagy through the AMPK signaling pathway.
Neoplasms
A High-Throughput Screening Triage Workflow to Authenticate a Novel Series of PFKFB3 Inhibitors.
Neoplasms
A Potential Oncogenic Role for PFKFB3 Overexpression in Gastric Cancer Progression.
Neoplasms
Aberrant methylation of human L- and M-fructose 1,6-bisphosphatase genes in cancer.
Neoplasms
Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis.
Neoplasms
Actinomycin D and nutlin-3a synergistically promote phosphorylation of p53 on serine 46 in cancer cell lines of different origin.
Neoplasms
Adapting glycolysis to cancer cell proliferation: the MAPK pathway focuses on PFKFB3.
Neoplasms
An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect.
Neoplasms
Angiogenesis revisited from a metabolic perspective: role and therapeutic implications of endothelial cell metabolism.
Neoplasms
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.
Neoplasms
Antiproliferative cyclodepsipeptides from the marine actinomycete Streptomyces sp. P11-23B downregulating the tumor metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis.
Neoplasms
ATM-NF?B axis-driven TIGAR regulates sensitivity of glioma cells to radiomimetics in the presence of TNF?.
Neoplasms
Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NF?B activation in the tumor stromal microenvironment.
Neoplasms
Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression.
Neoplasms
Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism.
Neoplasms
Biochemical and transcript level differences between the three human phosphofructokinases show optimisation of each isoform for specific metabolic niches.
Neoplasms
Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Neoplasms
Characterization of a new liver- and kidney-specific pfkfb3 isozyme that is downregulated by cell proliferation and dedifferentiation.
Neoplasms
Citrate targets FBPase and constitutes an emerging novel approach for cancer therapy.
Neoplasms
Click-Nucleic-Acid-Containing Codelivery System Inducing Collapse of Cellular Homeostasis for Tumor Therapy through Bidirectional Regulation of Autophagy and Glycolysis.
Neoplasms
Cloning and chromosomal characterization of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 gene (PFKFB3, iPFK2).
Neoplasms
Control of Glycolytic Flux by AMP-Activated Protein Kinase in Tumor Cells Adapted to Low pH.
Neoplasms
Crystal structure of the hypoxia-inducible form of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3): a possible new target for cancer therapy.
Neoplasms
Discover potential inhibitors for PFKFB3 using 3D-QSAR, virtual screening, molecular docking and molecular dynamics simulation.
Neoplasms
Downregulation of caveolin?1 upregulates the expression of growth factors and regulators in co?culture of fibroblasts with cancer cells.
Neoplasms
Downregulation of TIGAR sensitizes the antitumor effect of physapubenolide through increasing intracellular ROS levels to trigger apoptosis and autophagosome formation in human breast carcinoma cells.
Neoplasms
Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Neoplasms
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer.
Neoplasms
Dynamic ROS Regulation by TIGAR: Balancing Anti-cancer and Pro-metastasis Effects.
Neoplasms
Effects of the Novel PFKFB3 Inhibitor KAN0438757 on Colorectal Cancer Cells and Its Systemic Toxicity Evaluation In Vivo.
Neoplasms
Expression and hypoxia-responsiveness of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 in mammary gland malignant cell lines.
Neoplasms
Expression of 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase-3 and VEGF mRNA in rat liver, lung and heart: effect of methyl tertbutyl ether.
Neoplasms
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Neoplasms
Expression of TIGAR and its correlation with clinicopathology, prognosis, and 18F-FDG PET/CT parameters in patients with resectable pancreatic ductal adenocarcinoma.
Neoplasms
Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth.
Neoplasms
Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival.
Neoplasms
Genetic alteration in phosphofructokinase family promotes growth of muscle-invasive bladder cancer.
Neoplasms
Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity.
Neoplasms
Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma.
Neoplasms
Glycolysis links p53 function with NF-kappaB signaling: impact on cancer and aging process.
Neoplasms
Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Neoplasms
HIF-1? activates hypoxia-induced PFKFB4 expression in human bladder cancer cells.
Neoplasms
High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers.
Neoplasms
High expression of metabolic enzyme PFKFB4 is associated with poor prognosis of operable breast cancer.
Neoplasms
Higher plasma concentration of TP53-induced glycolysis and apoptosis regulator is associated with a lower risk of colorectal cancer metastasis.
Neoplasms
Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 gene via hypoxia-inducible factor-1alpha activation.
Neoplasms
Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers.
Neoplasms
Identification and characterization of the hypoxia-responsive element of the human placental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene.
Neoplasms
Identification of the TP53-induced glycolysis and apoptosis regulator in various stages of colorectal cancer patients.
Neoplasms
Identification of TP53-induced glycolysis and apoptosis regulator (TIGAR) as the phosphoglycolate-independent 2,3-bisphosphoglycerate phosphatase.
Neoplasms
In silico identification of potential inhibitor for TP53-induced glycolysis and apoptosis regulator in head and neck squamous cell carcinoma.
Neoplasms
In vitro angiogenesis inhibition with selective compounds targeting the key glycolytic enzyme PFKFB3.
Neoplasms
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism.
Neoplasms
Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death.
Neoplasms
Inhibition of Glycolysis Suppresses Cell Proliferation and Tumor Progression In Vivo: Perspectives for Chronotherapy.
Neoplasms
Inhibition of glycolytic activator PFKFB3 suppresses tumor growth and induces tumor vessel normalization in hepatocellular carcinoma.
Neoplasms
Inhibition of Growth by Combined Treatment with Inhibitors of Lactate Dehydrogenase and either Phenformin or Inhibitors of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase 3.
Neoplasms
Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer.
Neoplasms
Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy.
Neoplasms
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
Neoplasms
INTRACELLULAR TARGETING OF THE ONCOGENIC MUC1-C PROTEIN WITH A NOVEL GO-203 NANOPARTICLE FORMULATION.
Neoplasms
Investigating combinatorial approaches in virtual screening on human inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3): A case study for small molecule kinases.
Neoplasms
KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells.
Neoplasms
Kinome Screen Identifies PFKFB3 and Glucose Metabolism as Important Regulators of the Insulin/Insulin-like Growth Factor (IGF)-1 Signaling Pathway.
Neoplasms
Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide.
Neoplasms
Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming.
Neoplasms
Long noncoding RNA FIRRE contributes to the proliferation and glycolysis of hepatocellular carcinoma cells by enhancing PFKFB4 expression.
Neoplasms
Lymphotoxin-? promotes tumor angiogenesis in HNSCC by modulating glycolysis in a PFKFB3 dependent manner.
Neoplasms
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Neoplasms
Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma.
Neoplasms
microRNA-144 inhibits cell proliferation and invasion by directly targeting TIGAR in esophageal carcinoma.
Neoplasms
MicroRNA-26b inhibits osteosarcoma cell migration and invasion by down-regulating PFKFB3 expression.
Neoplasms
MicroRNA-3666 Suppresses Cell Growth in Head and Neck Squamous Cell Carcinoma Through Inhibition of PFKFB3-Mediated Warburg Effect.
Neoplasms
miR-1297 Suppresses Osteosarcoma Proliferation and Aerobic Glycolysis by Regulating PFKFB2.
Neoplasms
miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1.
Neoplasms
Monocyte fructose 1,6-bisphosphatase and cytidine deaminase enzyme activities: potential pharmacodynamic measures of calcitriol effects in cancer patients.
Neoplasms
Necroptosis pathway blockage attenuates PFKFB3 inhibitor-induced cell viability loss and genome instability in colorectal cancer cells.
Neoplasms
Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73.
Neoplasms
Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases.
Neoplasms
O-GlcNAcylation of PFKFB3 is required for tumor cell proliferation under hypoxia.
Neoplasms
Oncogenic role of the TP53-induced glycolysis and apoptosis regulator in nasopharyngeal carcinoma through NF-?B pathway modulation.
Neoplasms
Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors.
Neoplasms
Overexpression of ubiquitous 6-phosphofructo-2-kinase in the liver of transgenic mice results in weight gain.
Neoplasms
p53 coordinates DNA repair with nucleotide synthesis by suppressing PFKFB3 expression and promoting the pentose phosphate pathway.
Neoplasms
PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer.
Neoplasms
PFK15, a Small Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits Invasion in Gastric Cancer.
Neoplasms
Pfkfb (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) isoforms display a tissue-specific and dynamic expression during Xenopus laevis development.
Neoplasms
PFKFB3 activation in cancer cells by the p38/MK2 pathway in response to stress stimuli.
Neoplasms
PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT.
Neoplasms
PFKFB3 Inhibition Attenuates Oxaliplatin-Induced Autophagy and Enhances Its Cytotoxicity in Colon Cancer Cells.
Neoplasms
PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair.
Neoplasms
PFKFB3 inhibitors as potential anticancer agents: Mechanisms of action, current developments, and structure-activity relationships.
Neoplasms
PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis.
Neoplasms
PFKFB3 modulates glycolytic metabolism and alleviates endoplasmic reticulum stress in human osteoarthritis cartilage.
Neoplasms
PFKFB3 promotes proliferation, migration and angiogenesis in nasopharyngeal carcinoma.
Neoplasms
PFKFB3 regulates oxidative stress homeostasis via its S-glutathionylation in cancer.
Neoplasms
PFKFB4 as a promising biomarker to predict a poor prognosis in patients with gastric cancer.
Neoplasms
PFKFB4 negatively regulated the expression of histone acetyltransferase GCN5 to mediate the tumorigenesis of thyroid cancer.
Neoplasms
PFKFB4 Overexpression Facilitates Proliferation by Promoting the G1/S Transition and Is Associated with a Poor Prognosis in Triple-Negative Breast Cancer.
Neoplasms
PFKFB4 Promotes Breast Cancer Metastasis via Induction of Hyaluronan Production in a p38-Dependent Manner.
Neoplasms
Phosphoproteomic Analysis of X enopus laevis Reveals Expression and Phosphorylation of Hypoxia-Inducible PFKFB3 during Dehydration.
Neoplasms
Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer.
Neoplasms
Positive regulation of PFKFB3 by PIM2 promotes glycolysis and paclitaxel resistance in breast cancer.
Neoplasms
Prognostic Value of PFKFB3 to PFKFB4 mRNA Ratio in Patients With Primary Glioblastoma (IDH-Wildtype).
Neoplasms
Prognostic Values of TIGAR Expression and 18F-FDG PET/CT in Clear Cell Renal Cell Carcinoma.
Neoplasms
Reactive Oxygen Species-Dependent Down-Regulation of Tumor Suppressor Genes PTEN, USP28, DRAM, TIGAR, and CYLD Under Oxidative Stress.
Neoplasms
Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway.
Neoplasms
Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor.
Neoplasms
Regulatory role of p53 in cancer metabolism via SCO2 and TIGAR in human breast cancer.
Neoplasms
Relocation of phosphofructokinases within epithelial cells is a novel event preceding breast cancer recurrence that accurately predicts patient outcomes.
Neoplasms
RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival.
Neoplasms
Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets.
Neoplasms
SCO2 Induces p53-Mediated Apoptosis by Thr845 Phosphorylation of ASK-1 and Dissociation of the ASK-1-Trx Complex.
Neoplasms
Structure, regulation, and biological functions of TIGAR and its role in diseases.
Neoplasms
Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect.
Neoplasms
Studying Antitumor Effects of Sirna Gene Silencing of some Metabolic Genes in Pancreatic Ductal Adenocarcinoma.
Neoplasms
Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.
Neoplasms
Targeting of MCT1 and PFKFB3 influences cell proliferation and apoptosis in bladder cancer by altering the tumor microenvironment.
Neoplasms
Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination.
Neoplasms
Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor.
Neoplasms
Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3).
Neoplasms
The expression pattern of PFKFB3 enzyme distinguishes between induced-pluripotent stem cells and cancer stem cells.
Neoplasms
The Glycolytic Enzyme PFKFB3 Controls TNF-?-Induced Endothelial Proinflammatory Responses.
Neoplasms
The influence of PFK-II overexpression on neuroblastoma patients' survival may be dependent on the particular isoenzyme expressed, PFKFB3 or PFKFB4.
Neoplasms
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity.
Neoplasms
The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer.
Neoplasms
The PFKFB3 splice variant UBI2K4 is down-regulated in high-grade astrocytomas and impedes the growth of U87 glioblastoma cells.
Neoplasms
The role of 6-phosphofructo-2-kinase (PFK-2)/fructose 2,6-bisphosphatase (FBPase-2) in metabolic reprogramming of cancer cells.
Neoplasms
The role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in esophageal squamous cell carcinoma.
Neoplasms
The TP53-Induced Glycolysis and Apoptosis Regulator mediates cooperation between HTLV-1 p30II and the retroviral oncoproteins Tax and HBZ and is highly expressed in an in vivo xenograft model of HTLV-1-induced lymphoma.
Neoplasms
Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers.
Neoplasms
Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function.
Neoplasms
TIGAR has a dual role in cancer cell survival through regulating apoptosis and autophagy.
Neoplasms
TIGAR is correlated with maximal standardized uptake value on FDG-PET and survival in non-small cell lung cancer.
Neoplasms
TIGAR knockdown enhanced the anticancer effect of aescin via regulating autophagy and apoptosis in colorectal cancer cells.
Neoplasms
TIGAR knockdown radiosensitizes TrxR1-overexpressing glioma in vitro and in vivo via inhibiting Trx1 nuclear transport.
Neoplasms
TIGAR Promotes Tumorigenesis and Protects Tumor Cells From Oxidative and Metabolic Stresses in Gastric Cancer.
Neoplasms
TIGAR regulates DNA damage and repair through pentosephosphate pathway and Cdk5-ATM pathway.
Neoplasms
TP53 induced glycolysis and apoptosis regulator (TIGAR) knockdown results in radiosensitization of glioma cells.
Neoplasms
TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer.
Neoplasms
Ubiquitin-like protein FAT10 promotes osteosarcoma glycolysis and growth by upregulating PFKFB3 via stabilization of EGFR.
Neoplasms
Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Neoplasms
[Antineoplastic properties of extracellular fructoso-1,6-bisphosphatase of Bacillus subtilis 668 and preparation isolated from cultural liquids of Bacillus subtilis 7025]
Neoplastic Cells, Circulating
PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer.
Neuroblastoma
The influence of PFK-II overexpression on neuroblastoma patients' survival may be dependent on the particular isoenzyme expressed, PFKFB3 or PFKFB4.
Neuroinflammatory Diseases
Targeting neuroinflammation to treat cerebral ischemia - The role of TIGAR/NADPH axis.
Non-alcoholic Fatty Liver Disease
Indole Alleviates Diet-induced Hepatic Steatosis and Inflammation in a Manner Involving Myeloid Cell PFKFB3.
Obesity
Adipose tissue inflammation and systemic insulin resistance in mice with diet-induced obesity is possibly associated with disruption of PFKFB3 in hematopoietic cells.
Obesity
Association analysis of positional obesity candidate genes based on integrated data from transcriptomics and linkage analysis.
Obesity
[EXPRESSION OF GENES, WHICH CONTROL GLUCOSE METABOLISM, IN BLOOD CELLS OF THE OBESE BOYS WITH INSULIN RESISTANCE].
Obesity, Maternal
Loss of TIGAR Induces Oxidative Stress and Meiotic Defects in Oocytes from Obese Mice.
Obesity, Morbid
Association analysis of positional obesity candidate genes based on integrated data from transcriptomics and linkage analysis.
Osteoarthritis
Inhibition of 6-phosphofructo-2-kinase suppresses fibroblast-like synoviocytes-mediated synovial inflammation and joint destruction in rheumatoid arthritis.
Osteoarthritis
PFKFB3 modulates glycolytic metabolism and alleviates endoplasmic reticulum stress in human osteoarthritis cartilage.
Osteosarcoma
MicroRNA-26b inhibits osteosarcoma cell migration and invasion by down-regulating PFKFB3 expression.
Osteosarcoma
miR-1297 Suppresses Osteosarcoma Proliferation and Aerobic Glycolysis by Regulating PFKFB2.
Osteosarcoma
miR-26b inhibits proliferation, migration, invasion and apoptosis induction via the downregulation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 driven glycolysis in osteosarcoma cells.
Osteosarcoma
ROCK2 promotes osteosarcoma growth and metastasis by modifying PFKFB3 ubiquitination and degradation.
Osteosarcoma
Ubiquitin-like protein FAT10 promotes osteosarcoma glycolysis and growth by upregulating PFKFB3 via stabilization of EGFR.
Ovarian Neoplasms
A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models.
Ovarian Neoplasms
Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment.
Ovarian Neoplasms
Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity.
Ovarian Neoplasms
Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells.
Pancreatic Neoplasms
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer.
Pancreatic Neoplasms
Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers.
Pancreatic Neoplasms
Low glucose enhanced metformin's inhibitory effect on pancreatic cancer cells by suppressing glycolysis and inducing energy stress via up-regulation of miR-210-5p.
Pancreatic Neoplasms
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Pancreatic Neoplasms
PFKFB2 regulates glycolysis and proliferation in pancreatic cancer cells.
Pancreatic Neoplasms
Studying Antitumor Effects of Sirna Gene Silencing of some Metabolic Genes in Pancreatic Ductal Adenocarcinoma.
Pre-Eclampsia
Increased expression and phosphorylation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoforms in urinary exosomes in pre-eclampsia.
Pre-Eclampsia
MALAT1 sponges miR-26a and miR-26b to regulate endothelial cell angiogenesis via PFKFB3-driven glycolysis in early-onset preeclampsia.
Pre-Eclampsia
PFKFB3 regulates lipopolysaccharide-induced excessive inflammation and cellular dysfunction in HTR-8/Svneo cells: Implications for the role of PFKFB3 in preeclampsia.
Prostatic Hyperplasia
The metabolic role of PFKFB4 in androgen-independent growth in vitro and PFKFB4 expression in human prostate cancer tissue.
Prostatic Neoplasms
Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells.
Prostatic Neoplasms
CD44 regulates prostate cancer proliferation, invasion and migration via PDK1 and PFKFB4.
Prostatic Neoplasms
Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival.
Prostatic Neoplasms
Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 gene via hypoxia-inducible factor-1alpha activation.
Prostatic Neoplasms
Identification of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as a novel autophagy regulator by high content shRNA screening.
Prostatic Neoplasms
MicroRNA-488 inhibits proliferation and glycolysis in human prostate cancer cells by regulating PFKFB3.
Prostatic Neoplasms
miR-101 Enhances Cisplatin-Induced DNA Damage Through Decreasing Nicotinamide Adenine Dinucleotide Phosphate Levels by Directly Repressing Tp53-Induced Glycolysis and Apoptosis Regulator Expression in Prostate Cancer Cells.
Prostatic Neoplasms
The metabolic role of PFKFB4 in androgen-independent growth in vitro and PFKFB4 expression in human prostate cancer tissue.
Pulmonary Arterial Hypertension
Involvement of PFKFB3 in Pulmonary Arterial Hypertension Pathogenesis. Is It All about Glycolysis?
Pulmonary Arterial Hypertension
PFKFB3 in Smooth Muscle Promotes Vascular Remodeling in Pulmonary Arterial Hypertension.
Pulmonary Edema
Ablation of endothelial Pfkfb3 protects mice from acute lung injury in LPS-induced endotoxemia.
Pulmonary Fibrosis
PI3K-Akt-mTOR/PFKFB3 pathway mediated lung fibroblast aerobic glycolysis and collagen synthesis in lipopolysaccharide-induced pulmonary fibrosis.
Reperfusion Injury
Effect of microRNA-26a on vascular endothelial cell injury caused by lower extremity ischemia-reperfusion injury through the AMPK pathway by targeting PFKFB3.
Reperfusion Injury
Metformin regulates the Th17/Treg balance by glycolysis with TIGAR in hepatic ischemia-reperfusion injury.
Reperfusion Injury
Targeting PFKFB3 alleviates cerebral ischemia-reperfusion injury in mice.
Reperfusion Injury
TIGAR contributes to ischemic tolerance induced by cerebral preconditioning through scavenging of reactive oxygen species and inhibition of apoptosis.
Respiratory Syncytial Virus Infections
PFKFB3-Driven Macrophage Glycolytic Metabolism Is a Crucial Component of Innate Antiviral Defense.
Retinoblastoma
Structure, regulation, and biological functions of TIGAR and its role in diseases.
Retinoblastoma
TIGAR induces p53-mediated cell-cycle arrest by regulation of RB-E2F1 complex.
Rhabdomyosarcoma
PFK15, a PFKFB3 antagonist, inhibits autophagy and proliferation in rhabdomyosarcoma cells.
Sarcoidosis
Novel protein pathways in development and progression of pulmonary sarcoidosis.
Sarcoma 37
[Antineoplastic properties of extracellular fructoso-1,6-bisphosphatase of Bacillus subtilis 668 and preparation isolated from cultural liquids of Bacillus subtilis 7025]
Seizures
TIGAR suppresses seizures induced by kainic acid through inhibiting oxidative stress and neuronal apoptosis.
Sepsis
Identification of Potential Transcriptional Biomarkers Differently Expressed in Both S. aureus- and E. coli-Induced Sepsis via Integrated Analysis.
Severe Acute Respiratory Syndrome
Pathogenetic profiling of COVID-19 and SARS-like viruses.
Spinal Cord Injuries
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase Suppresses Neuronal Apoptosis by Increasing Glycolysis and "cyclin-dependent kinase 1-Mediated Phosphorylation of p27 After Traumatic Spinal Cord Injury in Rats.
Squamous Cell Carcinoma of Head and Neck
Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
In silico identification of potential inhibitor for TP53-induced glycolysis and apoptosis regulator in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Increased expression of PFKFB3 in oral squamous cell carcinoma and its association with lymphangiogenesis.
Squamous Cell Carcinoma of Head and Neck
Lymphotoxin-? promotes tumor angiogenesis in HNSCC by modulating glycolysis in a PFKFB3 dependent manner.
Squamous Cell Carcinoma of Head and Neck
MicroRNA-3666 Suppresses Cell Growth in Head and Neck Squamous Cell Carcinoma Through Inhibition of PFKFB3-Mediated Warburg Effect.
Squamous Cell Carcinoma of Head and Neck
Role of PFKFB3 and CD163 in Oral Squamous Cell Carcinoma Angiogenesis.
Starvation
Age-dependent glycolysis and gluconeogenesis enzyme activities in starved-refed rats.
Starvation
Changes in rat hepatic fructose 2,6-bisphosphate and 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase activity during three days of consumption of a high protein diet or starvation.
Starvation
Comparison between starvation and consumption of a high protein diet: plasma insulin and glucagon and hepatic activities of gluconeogenic enzymes during the first 24 hours.
Starvation
Degradation of the gluconeogenic enzymes fructose-1,6-bisphosphatase and malate dehydrogenase is mediated by distinct proteolytic pathways and signaling events.
Starvation
Effect of starvation on gene expression of regulatory enzymes of glycolysis/gluconeogenesis in genetically obese (fa/fa) Zucker rats.
Starvation
Induction of rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase mRNA by refeeding and insulin.
Starvation
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism.
Starvation
KRAB-type zinc-finger proteins PITA and PISA specifically regulate p53-dependent glycolysis and mitochondrial respiration.
Starvation
Predominant periportal expression of the fructose 1,6-bisphosphatase gene in rat liver: dynamics during the daily feeding rhythm and starvation-refeeding cycle.
Starvation
The TOR complex 1 is distributed in endosomes and in retrograde vesicles that form from the vacuole membrane and plays an important role in the vacuole import and degradation pathway.
Starvation
Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by upregulating respiration and improving cellular redox homeostasis.
Starvation
Vps34p is required for the decline of extracellular fructose-1,6-bisphosphtase in the vacuole import and degradation pathway.
Stomach Neoplasms
A Potential Oncogenic Role for PFKFB3 Overexpression in Gastric Cancer Progression.
Stomach Neoplasms
CircFLNA Acts as a Sponge of miR-646 to Facilitate the Proliferation, Metastasis, Glycolysis, and Apoptosis Inhibition of Gastric Cancer by Targeting PFKFB2.
Stomach Neoplasms
Distinctive interrelation of p53 with SCO2, COX, and TIGAR in human gastric cancer.
Stomach Neoplasms
Erratum: CircFLNA Acts as a Sponge of miR-646 to Facilitate the Proliferation, Metastasis, Glycolysis, and Apoptosis Inhibition of Gastric Cancer by Targeting PFKFB2 [Corrigendum].
Stomach Neoplasms
Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers.
Stomach Neoplasms
Long non-coding RNA MSC-AS1 facilitates the proliferation and glycolysis of gastric cancer cells by regulating PFKFB3 expression.
Stomach Neoplasms
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Stomach Neoplasms
miR-449c inhibits migration and invasion of gastric cancer cells by targeting PFKFB3.
Stomach Neoplasms
PFK15, a Small Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits Invasion in Gastric Cancer.
Stomach Neoplasms
PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells.
Stomach Neoplasms
PFKFB4 as a promising biomarker to predict a poor prognosis in patients with gastric cancer.
Stomach Neoplasms
Protein kinase D3 promotes gastric cancer development through p65/6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 activation of glycolysis.
Stomach Neoplasms
Rev-erb? inhibits proliferation by reducing glycolytic flux and pentose phosphate pathway in human gastric cancer cells.
Stomach Neoplasms
TIGAR Promotes Tumorigenesis and Protects Tumor Cells From Oxidative and Metabolic Stresses in Gastric Cancer.
Stroke
Ischemia/reperfusion-induced upregulation of TIGAR in brain is mediated by SP1 and modulated by ROS and hormones involved in glucose metabolism.
Thrombosis
Prognostic Values of TIGAR Expression and 18F-FDG PET/CT in Clear Cell Renal Cell Carcinoma.
Thyroid Neoplasms
PFKFB2 Promoter Hypomethylation as Recurrence Predictive Marker in Well-Differentiated Thyroid Carcinomas.
Thyroid Neoplasms
PFKFB4 negatively regulated the expression of histone acetyltransferase GCN5 to mediate the tumorigenesis of thyroid cancer.
Triple Negative Breast Neoplasms
6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
Triple Negative Breast Neoplasms
PFKFB4 Overexpression Facilitates Proliferation by Promoting the G1/S Transition and Is Associated with a Poor Prognosis in Triple-Negative Breast Cancer.
Tuberculosis
The Mycobacterium tuberculosis Rv1099c gene encodes a GlpX-like class II fructose 1,6-bisphosphatase.
Urinary Bladder Neoplasms
A glycolysis-based 4-mRNA signature correlates with the prognosis and cell cycle process in patients with bladder cancer.
Urinary Bladder Neoplasms
Genetic alteration in phosphofructokinase family promotes growth of muscle-invasive bladder cancer.
Urinary Bladder Neoplasms
HIF-1? activates hypoxia-induced PFKFB4 expression in human bladder cancer cells.
Urinary Bladder Neoplasms
PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer.
Urinary Bladder Neoplasms
Targeting of MCT1 and PFKFB3 influences cell proliferation and apoptosis in bladder cancer by altering the tumor microenvironment.
Uterine Cervical Neoplasms
Carbonic Anhydrase IX Promotes Human Cervical Cancer Cell Motility by Regulating PFKFB4 Expression.
Vascular Calcification
?-opioid receptor stimulation alleviates rat vascular smooth muscle cell calcification via PFKFB3-lactate signaling.
Virus Diseases
PFKFB3-Driven Macrophage Glycolytic Metabolism Is a Crucial Component of Innate Antiviral Defense.
Vitamin A Deficiency
Vitamin A regulates genes involved in hepatic gluconeogenesis in mice: phosphoenolpyruvate carboxykinase, fructose-1,6-bisphosphatase and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
additional information
additional information
tissue-specific expression of the different isozymes, overview
brenda
additional information
tissue-specific expression of the different isozymes, overview
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
additional information
head-to-head structure of the two subunits of the bifunctional enzyme, overview
additional information
head-to-head structure of the two subunits of the bifunctional enzyme, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
phylogenetic analysis, transcriptional control of isozymes, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Rider, M.H.; Bertrand, L.; Vertommen, D.; Michels, P.A.; Rousseau, G.G.; Hue, L.
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis
Biochem. J.
381
561-579
2004
Arabidopsis thaliana (Q9MB58), Bos taurus (P26285), Bos taurus (P49872), Bos taurus (Q28901), Desulfovibrio desulfuricans, Drosophila melanogaster (Q9VWH7), Homo sapiens (O60825), Homo sapiens (P16118), Homo sapiens (Q16875), Homo sapiens (Q16877), Leishmania major, Mus musculus (P70265), Mus musculus (Q9ESY2), Rattus norvegicus (O35552), Rattus norvegicus (P07953), Rattus norvegicus (P25114), Rattus norvegicus (Q9JJH5), Schizosaccharomyces pombe
brenda
EXTERNAL LINKS (specific for EC-Number 3.1.3.46)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
